0 CHECKOUT

Hematological Cancers Drug Pipeline Update

  • ID: 1197061
  • August 2016
  • Region: Global
  • Bioseeker
1 of 2

Unmet needs across the hematological malignancies remain high, with most traditional therapies conferring low levels of specificity and high toxicity.

There are today 700 companies plus partners developing 1147 hematological cancer drugs in 2542 developmental projects in cancer. In addition, there are 12 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 308 drugs. Hematological Cancers Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 485 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 463 out of the 468 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 80 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.

Drug Pipeline Update at a Glance

Investigators
Includes READ MORE >

Note: Product cover images may vary from those shown
2 of 2



Delivery Format: Desktop App plus Online Access to Updates (One Year)

Note: Product cover images may vary from those shown
3 of 2
Note: Product cover images may vary from those shown

PURCHASING OPTIONS

HAVE A QUESTION?

EMAIL US VIEW FAQs

RELATED PRODUCTS from Db

Our Clients

  • Pfizer Inc.
  • Grünenthal GmbH
  • GlaxoSmithKline PLC
  • Abbott Laboratories Ltd.
  • Roche Diagnostics Ltd.
  • Novo Nordisk A/S